- Home
- BKH vs RYTM Comparison
BKH vs RYTM Comparison
Compare BKH & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKH
- RYTM
- Stock Information
- Founded
- BKH 1941
- RYTM 2008
- Country
- BKH United States
- RYTM United States
- Employees
- BKH N/A
- RYTM N/A
- Industry
- BKH Electric Utilities: Central
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- BKH Utilities
- RYTM Health Care
- Exchange
- BKH Nasdaq
- RYTM Nasdaq
- Market Cap
- BKH 4.3B
- RYTM 3.8B
- IPO Year
- BKH N/A
- RYTM 2017
- Fundamental
- Price
- BKH $58.48
- RYTM $61.33
- Analyst Decision
- BKH Hold
- RYTM Strong Buy
- Analyst Count
- BKH 4
- RYTM 12
- Target Price
- BKH $63.75
- RYTM $76.75
- AVG Volume (30 Days)
- BKH 448.6K
- RYTM 632.6K
- Earning Date
- BKH 05-07-2025
- RYTM 05-07-2025
- Dividend Yield
- BKH 4.63%
- RYTM N/A
- EPS Growth
- BKH N/A
- RYTM N/A
- EPS
- BKH 3.95
- RYTM N/A
- Revenue
- BKH $2,206,500,000.00
- RYTM $136,863,000.00
- Revenue This Year
- BKH $7.02
- RYTM $37.88
- Revenue Next Year
- BKH $3.29
- RYTM $72.84
- P/E Ratio
- BKH $14.79
- RYTM N/A
- Revenue Growth
- BKH 3.28
- RYTM 48.88
- 52 Week Low
- BKH $51.66
- RYTM $35.35
- 52 Week High
- BKH $65.59
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- BKH 47.15
- RYTM 51.78
- Support Level
- BKH $57.37
- RYTM $58.72
- Resistance Level
- BKH $58.88
- RYTM $63.24
- Average True Range (ATR)
- BKH 0.98
- RYTM 2.43
- MACD
- BKH -0.03
- RYTM -0.15
- Stochastic Oscillator
- BKH 64.62
- RYTM 65.51
About BKH Black Hills Corporation
Black Hills Corp is a U.S.-based energy company that operates through its Electric Utilities and Gas Utilities segment. These segments operate in states in the Midwest and mountain regions in the U.S. The company's customers include residential, commercial, industrial, and municipal consumers. These customers are residential. Black Hills derives the majority of its revenue from its utility business group, specifically from gas utilities.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.